1. |
Williams ED. Mechanisms and pathogenesis of thyroid cancer in animals and man [J]. Mutat Res, 1995; 333(1-2): 123-129.
|
2. |
Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma [J]. Thyroid, 1999; 9(5): 421-427.
|
3. |
鄭澤霖, 蓋寶東, 孫輝. 分化型甲狀腺癌手術范圍探討 [J]. 中國普外基礎與臨床雜志, 2004; 11(6): 479-480.
|
4. |
Manzone TA, Dam HQ, Intenzo CM, et al. Postoperative management of thyroid carcinoma [J]. Surg Oncol Clin N Am, 2008; 17(1): 197-218.
|
5. |
Sherman SI. Thyroid carcinoma [J]. Lancet, 2003; 361(9356): 501-511.
|
6. |
薛緒潮, 方國恩. 甲狀腺癌的內分泌治療 [J]. 中國實用外科雜志, 2004; 24(10): 631-632.
|
7. |
Shiba E. Diagnosis and treatment of differentiated thyroid carcinoma [J]. Nippon Geka Gakkai Zasshi, 2005; 106(8): 459-462.
|
8. |
Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry [J]. Thyroid, 1998; 8(9): 737-744.
|
9. |
李小毅. 甲狀腺球蛋白在分化型甲狀腺癌診治中的作用 [J]. 中國普外基礎與臨床雜志, 2006; 13(3): 265-267.
|
10. |
Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls [J]. Endocrinol Metab Clin North Am, 1995; 24(4): 841-863.
|
11. |
Miyakawa M. Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma [J]. Nippon Rinsho, 2007; 65(11): 2073-2077.
|
12. |
Heemstra KA, Hamdy NA, Romijn JA, et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma [J]. Thyroid, 2006; 16(6): 583-591.
|
13. |
Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs [J]. Drug Saf, 1996; 15(1): 53-63.
|